Beaufour Ipsen Group, Roche deal

Beaufour and ROCZ will jointly develop Beaufour's diflomotecan and BN80927 cancer compounds. Diflomotecan, a topoisomerase-I inhibitor, is in Phase II cancer trials. BN80927, an inhibitor of topoiso...